Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial -

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Cancers | Gastrointestinal disorders
Summary
Chinese RCT (n=416) found that fruquintinib provided an increased overall survival vs placebo (9.3 vs 6.6 months, HR for death 0.65, p<0.001). Progression free survival was also increased (3.7 vs 1.8 months respectively, HR for progression or death 0.26, P<0.001)
UKMi comment
Fruquintinib is a selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3 currently under investigation
Related links: